Quarterly report pursuant to Section 13 or 15(d)

Note 15 - Income Taxes

v3.8.0.1
Note 15 - Income Taxes
9 Months Ended
Sep. 30, 2017
Notes to Financial Statements  
Income Tax Disclosure [Text Block]
1
5
.
Income Taxes
 
Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Due to the uncertainty surrounding the realization of the deferred tax assets in future tax returns, all of the deferred tax assets have been fully offset by a valuation allowance at
September 30, 2017
and
December 
31,
2016.
 
Current accounting standards include guidance on the accounting for uncertainty in income taxes recognized in the financial statements. Such standards also prescribe a recognition threshold and measurement model for the financial statement recognition of a tax position taken, or expected to be taken, and provides guidance on derecognition, classification, interest and penalties, accounting in interim periods, disclosure and transition. The Company believes that the ultimate deductibility of all tax positions is highly certain, although there is uncertainty about the timing of such deductibility. As a result,
no
liability for uncertain tax positions was recorded as of
September 30, 2017
or
December 
31,
2016
and we do
not
expect any significant changes in the next
twelve
months. Should we need to accrue interest or penalties on uncertain tax positions, we would recognize the interest as interest expense and the penalties as a selling, general and administrative expense. As of
September 30, 2017,
tax years
2013
-
2016
remained subject to examination by federal and state tax authorities.
 
Benefit from
income taxes was
$789,000
for the
three
-month period ended
September 30, 2017,
representing an effective tax rate of
34%,
as compared to
$0
for the
three
-month period ended
September 30, 2016,
representing an effective tax rate of
0%.
The increase in the effective rate for the period ended
September 30, 2017
compared with the same period in
2016
is primarily due to the gain on sale of our Lymphoseek product.
 
As of
September 30, 2017,
we had approximately
$127.7
million of federal and
$16.2
 million of state net operating loss carryforwards.